Skip to Content
Morningstar

Sino Biopharmaceutical: Placing Coverage Under Review

""
Securities In This Article
Sino Biopharmaceutical Ltd
(01177)

We are placing coverage of narrow-moat-rated Sino Biopharmaceutical 01177 under review pending the transfer of coverage to a new analyst. We expect to revisit our coverage of this company over the next three months. Our most recent fair value estimate was HKD 6.50.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

Tesla: Shareholder Vote Reduces Key Person Risk

We continue to view Tesla stock as slightly undervalued.
Seth Goldstein, CFA

After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?

With strong execution but a stretched valuation, here’s Morningstar’s take on CrowdStrike stock.
Malik Ahmed Khan, CFA

Adobe’s Strong Quarterly Results Drive Share Gains

We’re raising our fair value for the software stock, which upped its full-year outlook.
Dan Romanoff, CPA

About the Author

Yurou Zheng

Equity Analyst
More from Author

Yurou Zheng is an equity research analyst for Morningstar (Shenzhen) Ltd., a wholly owned subsidiary of Morningstar, Inc. She assists in the coverage of stocks in the auto, healthcare, industrials, and utilities & energies sectors for the Asia team.

Before joining the Morningstar Equity Research team in 2022, Zheng was in the Morningstar Fund Data team for a regulation-driven project in the Australian market. Prior to Morningstar, she worked in a start-up venture capital fund covering the healthcare sector and worked at PwC Deals in Italy.

Zheng holds a bachelor’s degree in International Economics and Finance from Bocconi University. She also passed the bar for the Fund Practitioner Qualification by the Asset Management Association of China (AMAC) in 2021.

Sponsor Center